4 assets in T-Cell Leukemia

Therapeutic assets addressing T-Cell Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
cd19-ucart T-Cell Leukemia	Beijing Boren Hospital	P1	CCC (53)
Mogamulizumab T-Cell Leukemia	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Cart84 T-Cell Leukemia	Gyala Therapeutics	P1/2	CCC (48)
cd4car T-Cell Leukemia	Huda Salman	P1	CC (43)